Kura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
01 déc. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification...
Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
15 nov. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will...
Kura Oncology Reports Third Quarter 2016 Financial Results
07 nov. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
04 nov. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s...
Kura Oncology to Participate in Two Upcoming Investor Conferences
01 nov. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and...
Kura Oncology to Report Third Quarter 2016 Financial Results
31 oct. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the 2016 Aegis Growth Conference
14 sept. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth...
Kura Oncology Reports Second Quarter 2016 Financial Results
10 août 2016 16h03 HE
|
Kura Oncology, Inc.
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at...
Kura Oncology to Report Second Quarter 2016 Financial Results
03 août 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial...
Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
14 janv. 2016 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in...